Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia

Head and Neck Cancer Clinical Trial

Official title:

Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00052611
• Other study ID #: 02-024
• Secondary ID: P30CA006516DFCI-
• Status: Completed
• Phase: Phase 2
• First received: January 24, 2003
• Last updated: March 28, 2018
• Start date: June 2002
• Est. completion date: March 2005

Study information

• Verified date: March 2018
• Source: Dana-Farber Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patient at increased risk for developing a new head and neck squamous cell carcinoma are invited to take part in this study.

The investigators of this trial will attempt to study the effectiveness of Celecoxib in preventing cancer in patients who have oral leukoplakia and/or head and neck dysplasia.

Description:

Celecoxib is being studied in precancerous lesions of the head and neck in part because, it has been shown to prevent the progression of another type of precancerous polyps (a type of abnormal growth) in patients at high risk for colorectal cancer. There are, however, no published studies yet looking at this drug in humans for the prevention of head and neck cancers. The U.S. Food and Drug Administration has approved celecoxib for arthritis and the prevention of polyps in patients with familial adenomatous polyposis (a type of precancerous syndrome in some families that can lead to colon cancer).

This study is being done to find out several things:

• Is celecoxib, also known by the trade name Celebrex ®, effective in reducing the expression of precancerous markers (biological signals for specific cellular activities) in oral leukoplakia and dysplasia (abnormal growth) of the oral mucosa?

• Is celecoxib effective in reducing the size of oral leukoplalda lesions and/or presence of dysplasia?

• Does the reduction in precancerous markers correspond with reduction of oral leukoplalda and/or presence of dysplasia?

• What are the side effects of celecoxib in this patient population?

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: March 2005
• Est. primary completion date: March 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects will be = 18 years.

• Subjects will have oral leukoplakia on clinical examination and/or more than one previous HNSCC with dysplasia histologically proven on random biopsy within 6 months at the time of entry.

• Patients who have had surgical treatment for a previous HNSCC, stage I-III, will be eligible for enrollment if they are cancer-free = 9 months at the time of entry. Patients with CIS or new leukoplakia will be immediately eligible if they are more then 9 months from treatment of a prior carcinoma.

• Leukoplakia lesions must be = 0.5 cm in at least one dimension to be considered measurable. Measurable lesions are not required for entry.

• The ECOG performance status will be = 2. (See Appendix B for ECOG performance status.)

• The life expectancy will be =12 months.

• Subjects will have adequate organ function with a platelet count of >100,000, ANC > 1500, PT and PTT < 1.5 X ULN, creatinine <1.5, urine protein <2+, and total bilirubin and liver transaminases <1.5 X ULN.

• Premenopausal women will be required to use a reliable method of birth control throughout the course of therapy.

• Subjects will provide written, voluntary informed consent

Exclusion Criteria:

• Patients who have had surgical treatment for a previous HNSCC, stage I-III, will not be eligible for enrollment if they are cancer-free < 9 months at the time of entry.

• Subjects with contraindication to nasopharyngoscopy and biopsy will not be enrolled.

• Significant comorbidities, including known coronary artery disease, angina, history of myocardial infarction, congestive heart failure of at least grade 2 according to the New York Heart Association Criteria, advanced COPD requiring use of home oxygen, active alcohol abuse, bleeding diathesis, any history of gastrointestinal ulcer, acute or chronic renal insufficiency, or acute or chronic liver disease, will preclude enrollment in the trial.

• Enrollment in the trial will be limited to patients who are free from current tobacco use. If the patient has a history of previous tobacco use, they Must be abstinent for at least 1 month prior to enrollment and meet the criteria established by the Food and Drug Administration for assessing smoking cessation, i.e. have not taken even a puff or taste of tobacco, including cigarette, cigar, pipe, chewing tobacco or other tobacco products, in the past 4 weeks.

• Any active malignancy, except non-melanoma skin cancer, will preclude enrollment.

• Persons who have taken full-dose aspirin, NSAIDs, COX-2 inhibitors and systemicallyabsorbed steroids, including inhaled steroids and nasal steroids other than mometazone, at least 3 times per week for 2 or more consecutive weeks within 3 months of enrollment will be excluded. Persons who have taken retinoids or selenium within 3 months of enrollment, or who have a history of anaphylactoid reaction to aspirin, NSAIDs or COX- 2 inhibitors will not be enrolled.

• Persons taking ACE inhibitors will not be enrolled. Diuretics for CHF, or treatment with lithium or fluconazole will also preclude enrollment. Patients on coumadin will be required to have PT/INR monitoring BIW after starting celecoxib, until the patient is on a stable dose of coumadin for 7 days, and must have no contraindication to holding the coumadin for study biopsies.

• Pregnant, lactating women or premenopausal women with a positive f3HCG will not be enrolled in the study.

Related Conditions & MeSH terms

• Head and Neck Cancer
• Head and Neck Neoplasms

Intervention

Drug:
• Celecoxib

Locations

Country	Name	City	State
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital Cancer Center	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Rate Of PGE2		2 years
Secondary	Change In SEB Expression Of COX-2		2 years
Secondary	Response Of Measurable Lesions		2 years
Secondary	Assessing Safety		2 years
Secondary	Change In SEB Expression Of Akt		2 years
Secondary	Change In SEB Expression Of Ki-67		2 years
Secondary	Change In SEB Expression Of BCL2		2 years
Secondary	Change In SEB Expression Of BAX		2 years
Secondary	Change In SEB Expression Of VEGF		2 years
Secondary	Change In SEB Expression Of CD31		2 years